Shanghai Qingyu Pharmaceutical Technology

Shanghai Qingyu Pharmaceutical Technology is a clinical-stage biotechnology company based in Shanghai, China, focused on the discovery and development of innovative small molecule therapeutics. The company primarily targets the oncology space, utilizing its internal research capabilities to develop highly selective inhibitors for cancer treatment. Its lead program, QY-101, is a potent CDK4/6 inhibitor currently undergoing Phase 1 clinical trials for patients with advanced solid tumors. Headquartered in the Zhangjiang High-Tech Park, Qingyu Pharmaceutical leverages a team of experienced scientists to advance its pipeline of novel drug candidates. The company aims to provide effective and accessible treatment options for patients globally through rigorous scientific innovation.